Description
Eptifibatide is an inhibitor of glycoprotein GP IIb/IIIa that exhibits antiplatelet/antithrombotic activity. Eptifibatide inhibits fibrinogen-mediated platelet aggregation and is clinically used to treat acute coronary syndrome.
Product Unit Size | Cost | Quantity | Stock |
---|
Eptifibatide is an inhibitor of glycoprotein GP IIb/IIIa that exhibits antiplatelet/antithrombotic activity. Eptifibatide inhibits fibrinogen-mediated platelet aggregation and is clinically used to treat acute coronary syndrome.
Cas No. | 188627-80-7 |
---|---|
Purity | ≥98% |
Formula | C35H49N11O9S2 |
Formula Wt. | 832.4 |
Chemical Name | N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-L-Cysteinamide, cyclic (1-6)-disulfide |
IUPAC Name | 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3- ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13, 21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid |
Synonym | Integrilin |
Solubility | Soluble in water (5 mg/mL), methanol, DMSO (10 mg/mL), ethanol (5 mg/mL), DMF (30 mg/mL). |
Appearance | White to off white powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116. PMID: 23083110.
Gurbel PA, Galbut B, Bliden KP, et al. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis. 2002 Dec;14(3):213-9. PMID: 12913401.
Endogenous steroid hormone involved in reproduc...
STING agonist
Synthesis impurity
Endogenous peptide hormone, involved in intesti...
Neuromodulator, biomarker
Purine nucleoside analog; DNA chain terminator....
NSAID; TRPA1 agonist, COX-2 inhibitor.
Peptide; serine protease inhibitor.
HDAC inhibitor, RNA splicing inhibitor.
CSF-1R Inhibitor.
Macrolide; protein synthesis inhibitor.
Statin; HMG-CoA reductase inhibitor.
Cysteine-ITC conjugate, antioxidant.
Salicylic acid prodrug, NSAID; weak COX-1/2 inh...
Survivin inhibitor.
D2/3 agonist.
Impurity of diclofenac
PDE3 inhibitor.
NSAID; COX-1/2 inhibitor, potential K+ channel ...
TxA2 antagonist.